Romosozumab (Evenity): The Bone-Building Osteoporosis Treatment

What is romosozumab (Evenity), and how does it work?

Romosozumab is an osteoporosis medicine that does something most other treatments cannot: it actively builds new bone as well as slowing bone loss. The Royal Osteoporosis Society explains that it works "by speeding up the cells that build bone (osteoblasts), and slowing down the cells that break down bone (osteoclasts)" — so it "can help strengthen your bones and reduce your risk of breaking more bones" Royal Osteoporosis Society. Technically, romosozumab is a monoclonal antibody that blocks a protein called sclerostin, which normally acts as a brake on bone formation; release that brake and the skeleton tips towards building.

That dual action is what earns romosozumab its label as an anabolic (bone-building) treatment, and it is why it is reserved for people whose bones need rebuilding, not just protecting. It treats the imbalance behind what causes osteoporosis from both directions at once.

How is romosozumab different from bisphosphonates and denosumab?

The everyday osteoporosis drugs are antiresorptives — they slow the cells that break bone down, but they don't build new bone. Romosozumab does both. Bisphosphonates such as alendronic acid bind into the bone mineral and dampen breakdown; denosumab (Prolia) is an antibody that blocks a different signal (RANKL) to stop the bone-removing cells forming. Both are valuable, but they work by putting a brake on loss.

Romosozumab is the treatment that pushes the accelerator on bone formation while also easing off breakdown — a fundamentally different mechanism, and the reason it tends to build density faster over its short course. It is not a like-for-like alternative to the tablets: it sits above them, for people at the highest risk.

How is romosozumab given?

Romosozumab is given as two injections under the skin, once a month, for 12 months — and only for 12 months. The EVENITY product information states the recommended dose is "210 mg romosozumab (administered as two subcutaneous injections of 105 mg each) once monthly for 12 months" EVENITY SmPC (emc), and the Royal Osteoporosis Society confirms it means "two injections just under the skin, once a month for 12 months" Royal Osteoporosis Society.

The two injections are given one straight after the other, into the abdomen, thigh or upper arm, at slightly different spots. Treatment is started and supervised by a specialist experienced in osteoporosis — usually at a hospital rather than a GP surgery — and you are advised to have enough calcium and vitamin D before and during the course EVENITY SmPC (emc).

Who is romosozumab for?

Romosozumab is for postmenopausal women with severe osteoporosis who are at very high, imminent risk of fracture. On the NHS in England and Wales, NICE (TA791) recommends it "for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture)" NICE TA791. The Scottish Medicines Consortium accepted it for restricted use in NHSScotland on the same "imminent risk of another fragility fracture within 24 months" basis SMC2280.

One important scope point: in the UK romosozumab is licensed for women only. The Royal Osteoporosis Society notes that "if you're a man with osteoporosis, you're very unlikely to be offered romosozumab" Royal Osteoporosis Society — a real difference from denosumab and bisphosphonates, which are used in men too. Whether it is right for a particular woman depends on her fracture risk, often estimated with a tool like FRAX — see our guide to fracture risk and FRAX.

Why must romosozumab always be followed by another treatment?

Because romosozumab only lasts 12 months, and its benefit fades once you stop, it must be followed by an antiresorptive to lock the gains in. The product information is explicit: after the course, "transition to antiresorptive therapy is recommended in order to extend the benefit achieved with romosozumab beyond 12 months" EVENITY SmPC (emc). The Royal Osteoporosis Society puts it plainly: "the benefits of romosozumab start to wear off when you stop taking it. So if you don't start another treatment, your bones will become weaker" Royal Osteoporosis Society.

That follow-on is usually a bisphosphonate. This "build then maintain" sequence is also why it works well: NICE noted that "romosozumab followed by alendronic acid is more effective at reducing the risk of fractures than alendronic acid alone" NICE TA791. The practical message from the Royal Osteoporosis Society is to plan the next step before you begin — the benefit is not something you can simply bank and walk away from.

The cardiovascular warning: who should not have romosozumab

This is the safety point that must not be understated: romosozumab is contraindicated in anyone who has had a heart attack or stroke. The EVENITY product information lists "history of myocardial infarction or stroke" as a contraindication, because "in randomised controlled studies, an increase in serious cardiovascular events (myocardial infarction and stroke) has been observed in romosozumab treated patients compared to controls" EVENITY SmPC (emc). The Royal Osteoporosis Society says the same in plain terms: "you won't be able to have romosozumab if you have a history of heart attack or stroke" Royal Osteoporosis Society.

Even without a prior event, the decision weighs your fracture risk against your heart risk. The product information says prescribers should consider "her fracture risk over the next year and her cardiovascular risk based on risk factors (e.g. established cardiovascular disease, hypertension, hyperlipidaemia, diabetes mellitus, smoking, severe renal impairment, age)," and that romosozumab "should only be used if the prescriber and patient agree that the benefit outweighs the risk." If a heart attack or stroke happens during treatment, "treatment with romosozumab should be discontinued" EVENITY SmPC (emc).

What are the side effects of romosozumab?

Most side effects are mild, and the more common ones are aches and cold-like symptoms rather than anything dramatic. The Royal Osteoporosis Society lists joint pain, headache and cold-like symptoms, adding that side effects "aren't very common" and "shouldn't last for long" Royal Osteoporosis Society. The product information records nasopharyngitis (cold-like symptoms) and joint pain as the most frequent reactions, and low blood calcium (hypocalcaemia) as uncommon. Pre-existing low calcium is in fact a contraindication — it must be corrected, and calcium and vitamin D given, before you start EVENITY SmPC (emc).

Two rare but serious effects, familiar from other osteoporosis drugs, are also possible: osteonecrosis of the jaw (delayed healing in the mouth, usually after dental work) and atypical thigh-bone fractures. New, unexplained thigh or groin pain should prompt a doctor's appointment Royal Osteoporosis Society. For most women who genuinely need it, these sit at the far, uncommon end of the picture — the cardiovascular contraindication above is the more important consideration.

How do you track the bone you've built?

Romosozumab is a short, intensive course that both builds bone and sets up the next stage of your treatment plan — so knowing where your bone density actually stands, before and after, is genuinely useful. You cannot feel your bones changing; the only way to see whether a 12-month course has done its job, and to inform the follow-on decision, is to measure it.

That monitoring role is where a radiation-free approach fits. Standard DEXA uses a small X-ray dose; REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely to follow change over time. It complements — rather than replaces — your specialist's plan and any decision about follow-on treatment. You can book a radiation-free bone health assessment or read more about our bone health assessment.

---

This article is for general information and is not a substitute for advice from your GP, nurse or specialist — never start, stop or change a prescribed medicine on your own. Romosozumab is a specialist-initiated treatment. This is part of our bone health series; to understand the bigger picture, see what causes osteoporosis.